Please ensure Javascript is enabled for purposes of website accessibility

Why Shares of Acasti Pharma Slumped Tuesday

By Jim Halley – Updated Aug 31, 2021 at 2:46PM

Key Points

  • Acasti just performed a reverse stock split.
  • The company is a clinical-stage biotech with no approved drugs.

Motley Fool Issues Rare “All In” Buy Alert

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The clinical-stage pharmaceutical company completed its merger with Grace Therapeutics last week.

What happened

Acasti Pharma (ACST 1.38%) fell by more than 18% in Tuesday trading. The stock, which closed at a split-adjusted price of $3.21 on Monday (more on that below), opened at $2.94 on Tuesday, then dropped to a low of $2.58. The stock has lost more than 33% of its value over the past three months, and is far from the split-adjusted 52-week high of $9.76 it set in February.

A scientists works in a lab.


So what

Investors were unimpressed by the company's two big announcements on Friday, and Tuesday's move lower was just a continuation of the market's reaction to that news. The company said that it had closed its merger with Grace Therapeutics; former Acasti shareholders now own 59% of the combined company. The second -- and more concerning -- part of the announcement was that the company would perform an 8-1 reverse split at the start of trading on Aug. 31. This was being done, management said, to bring Acasti back into compliance with the NASDAQ's minimum bid price rule.

Reverse stock splits are rarely a good sign because they are often done by struggling companies that need to increase their share prices to remain eligible to be listed on a particular exchange. If a stock's price drops after a reverse split, as was the case Tuesday with Acasti, more investors may sell, lowering the stock's price further.

Now what

Acasti isn't making money yet, but it does have potential. The biotech company is working on treatments for three rare conditions: subarachnoid hemorrhage (life-threatening bleeding between the brain and skull, often caused by an aneurysm or the ballooning of a weakened blood vessel wall), ataxia-telangiectasia (a progressive, neurodegenerative genetic disease that impacts motor function, mostly affecting children) and postherpetic neuralgia (debilitating nerve pain caused by shingles).

The main concern for Acasti is how it will fund the clinical trials for the three candidates in its pipeline, as it has only $60 million on the books, which it says is sufficient to cover operations for at least two years. The focus for now will be on bringing lead candidate GTX-104 -- a hopeful subarachnoid hemorrhage treatment -- through to its phase 3 trial, which is expected to start sometime in the second half of 2022.

The company last August ended its TRILOGY 2 study of its drug candidate CaPre as a treatment for hypertriglyceridemia (high levels of triglycerides in the blood), saying that CaPre hadn't met the trial's primary endpoint.

The stock currently appears to be a risky investment. The best hope for Acasti shareholders is that by holding onto it for the long term, they may at some point reap the benefits if the company eventually brings one of its candidates to market.

Jim Halley has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Acasti Pharma (Class A) Stock Quote
Acasti Pharma (Class A)
$0.42 (1.38%) $0.01

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/27/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.